Valuation: Lantheus Holdings, Inc.

Market Cap 6.51B 5.8B 5.37B 4.89B 9.17B 617B 9.32B 64.45B 25.34B 322B 24.42B 23.91B 1,031B P/E 2026 *
21.1x
P/E 2027 * 17.9x
Enterprise Value 6.29B 5.61B 5.19B 4.72B 8.86B 596B 9.01B 62.29B 24.49B 312B 23.6B 23.1B 996B EV / Sales 2026 *
4.27x
EV / Sales 2027 * 3.57x
Free-Float
88.47%
Yield 2026 *
-
Yield 2027 * -
1 day+0.16%
1 week-0.28%
Current month+0.30%
1 month-0.45%
3 months-4.38%
6 months+18.88%
Current year+50.00%
1 week 99.6
Extreme 99.595
100.28
1 month 99.31
Extreme 99.31
100.96
Current year 63.37
Extreme 63.37
111.86
1 year 50.16
Extreme 50.155
111.86
3 years 47.25
Extreme 47.25
126.89
5 years 22.52
Extreme 22.515
126.89
10 years 7.95
Extreme 7.95
126.89
Manager TitleAgeSince
Chief Executive Officer 66 01/01/2026
Director of Finance/CFO 60 21/09/2018
Chief Tech/Sci/R&D Officer 64 01/08/2025
Director TitleAgeSince
Director/Board Member 80 01/05/2012
Chairman 66 01/03/2024
Director/Board Member 61 01/01/2017
Date Insider Type Main position Quantity % Market Cap. Importance
31/8/26 Tax

Chief Financial Officer

-721 0.0011%
17/8/26 Tax

Controller/Auditor

-463 0.0007%
17/8/26 Tax

Chief Technology Officer

-2,536 0.0039%
Change 5-day change 1-year change 3-year change Capi.($)
+0.16%-0.28%+76.37%+44.23% 6.51B
-1.04%+1.98%-19.82%+8.80% 181B
-1.96%+1.06%-3.15%+28.40% 116B
+1.37%+5.61%-21.71%+11.19% 113B
-1.52%+3.61%-51.56%-6.22% 79.83B
-0.99%+3.55%+2.81%+77.26% 65.06B
-0.27%+2.10%+15.54%+66.81% 54.35B
-0.59%+0.87%-0.25%-26.00% 52.23B
-0.64%+6.15%-13.56%+30.65% 44.15B
-0.53%-0.37%+25.10%-0.51% 32.47B
Average -0.60%+4.62%+0.98%+23.46% 74.51B
Weighted average by Cap. -0.72%+5.45%-11.82%+19.57%

Financials

2026 *2027 *
Net sales 1.47B 1.31B 1.22B 1.11B 2.08B 140B 2.11B 14.6B 5.74B 73.04B 5.53B 5.41B 233B 1.65B 1.47B 1.37B 1.24B 2.33B 157B 2.37B 16.38B 6.44B 81.94B 6.2B 6.07B 262B
Net income 320M 285M 264M 240M 450M 30.29B 458M 3.16B 1.24B 15.83B 1.2B 1.17B 50.62B 392M 350M 324M 295M 553M 37.19B 562M 3.89B 1.53B 19.44B 1.47B 1.44B 62.14B
Net Debt -219M -195M -180M -164M -308M -20.72B -313M -2.16B -851M -10.83B -820M -803M -34.63B -598M -533M -494M -449M -842M -56.67B -856M -5.92B -2.33B -29.62B -2.24B -2.2B -94.68B
Projected Income Statement - Annual - Lantheus Holdings, Inc.
Logo Lantheus Holdings, Inc.
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company, dedicated to helping clinicians find, fight, and follow disease to deliver better patient outcomes. Its product categories include oncology, neurology, cardiology, and strategic partnerships and others. Its products include PYLARIFY, Neuraceq, and DEFINITY. PYLARIFY TruVu is indicated for PET imaging of PSMA-positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy, or suspected recurrence based on elevated serum prostate-specific antigen (PSA). Neuraceq is an Alzheimer's disease radiodiagnostic. Its commercial products are used by cardiologists, internists, neurologists, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists across a range of clinical care settings. Its diagnostic products provide information that enables healthcare professionals (HCPs) to better detect, characterize, or rule out diseases.
Employees
1,193
Date Price Change Volume
20/10/26 USD 99.81 +0.11% 629,781
16/10/26 USD 99.70 -0.29% 1,711,646
15/10/26 USD 99.99 -0.01% 866,503
14/10/26 USD 100.00 -0.02% 936,668
13/10/26 USD 100.02 -0.09% 1,536,472
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Lantheus Holdings, Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
99.70USD
Average target price
106.99USD
Spread / Average Target
+7.31%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Lantheus Holdings, Inc.
  1. Stock Market
  2. Stocks
  3. LNTH Stock